0.124 billion USD! FOSUN PHARMA and United Family Healthcare "completely part ways" | Quick announcement.

① FOSUN PHARMA's subsidiary plans to sell a 6.6% stake in the symbol company for 0.124 billion USD; ② The relationship between FOSUN PHARMA and Huameijia can be traced back to 2009; ③ After this Trade is completed, FOSUN PHARMA will completely exit Huameijia.

cls.cnMar 13 11:26 ET

It's adding insult to injury! JiangSu WuZhong Pharmaceutical Development is beset by three major Bearish factors. Will the agency rights for Tongyan needles change? | Quick Announcement

① JiangSu WuZhong Pharmaceutical Development is currently facing uncertainties such as allegations of violating information disclosure laws, subsidiary's alleged assistance in tax fraud, and changes in agency rights for AestheFill within China. ② Compared to the beginning of the year, the company's stock price has fallen over 35%, reaching a new low for this year.

cls.cnMar 12 10:49 ET

The "hot battle" of humanoid robots has begun: frequent release of new products. Is the year of mass production really here? | Industry observation

① Siasun Robot&Automation and Zhiyuan Robot both launched new humanoid robots, and related Concept stocks rose in response; ② mass production of humanoid robots still faces challenges, and domestic manufacturers aim to produce thousands of units this year; ③ there are also disputes within the Industry regarding the implementation scenarios.

cls.cnMar 12 00:30 ET

The late-night announcement of the "Demon King" triggered a "Moment of Crisis" as Hainan Shuangcheng Pharmaceuticals' restructuring failure sounded the alarm for (Delisted).

1. Hainan Shuangcheng Pharmaceuticals suddenly announced at midnight that it would terminate the acquisition of Aola shares. After planning this Trade last year, the stock price once surged 7 times with "21 boards in 23 days"; 2. The cost differences of the equity obtained by the 25 counterparties faced by the company are significant, and the cost pressure for institutions that entered during Pre-IPO financing may be higher; 3. The company's operating situation is poor and is facing Special Treat, and the failed restructuring may push it into a more dangerous situation.

cls.cnMar 10 20:51 ET

Guangdong promotes legislation in the AI and Siasun Robot&Automation sectors, with ongoing policy support for the Industry.

① The General Office of the People's Government of Guangdong Province issued several policy measures to promote the innovative development of the AI and Siasun Robot&Automation industries. It mentions that legislation in the fields of AI and Siasun Robot&Automation should be accelerated to provide institutional safeguards for the development of the AI and Siasun Robot&Automation industries. ② Deutsche Bank believes that humanoid robots will experience large-scale production and widespread application in the next decade. By 2035, the market size for humanoid robots is expected to reach 75 billion dollars.

cls.cnMar 10 19:56 ET

JiangSu WuZhong Pharmaceutical Development is in trouble! A subsidiary has been sued for assisting in a tax fraud case and is also under investigation for violation of information disclosure regulations.

① JiangSu WuZhong Pharmaceutical Development announced that its subsidiary and the Chairman are being prosecuted for assisting in tax fraud of 0.242 billion yuan, and are also being investigated by the Securities Regulatory Commission for information disclosure violations, which may pose a risk of (Delisted); ② although the two incidents are closely timed, legal experts say that no correlation can be discerned at present; ③ since the third quarter of last year, JiangSu WuZhong's performance has shown significant improvement; ④ some investors have declared "they will protect their legitimate rights and interests" due to the significant fluctuations in stock prices.

cls.cnMar 7 10:07 ET